OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites	19
Formulation of apigenin-loaded solid lipid nanoparticles: characterisation, molecular docking, and anticancer assay	16
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development	15
Academic foreign compound metabolism – ‘ quo vadis ’?	13
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver	13
Developmental stage and infection status may affect drug distribution in the prostate of rats	11
In vitro hepatic metabolism of the natural product quebecol	10
Meeting report: oligonucleotide ADME workshop	8
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses	8
Methyl mercury pharmacokinetics in man: a five-compartment hybrid model	8
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor	8
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model	8
In silico models to predict tubular secretion or reabsorption clearance pathway using physicochemical properties and structural characteristics	8
Diisononyl phthalate down-regulates the expression of antioxidant genes NFE2L2 , TXN , and TXNRD2 , while d	8
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 1 and 2 (rs4244285, 681G>A) alleles in vitro	8
Apigenin Derivatives as Promising Norovirus RdRp Inhibitors: Insights from In Silico Docking and Molecular Dynamics Studies	8
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2	8
Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients	8
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences	8
An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds	7
Machine learning-driven bioavailability prediction in early-stage drug development: a KNIME-based computational workflow for digital health applications	7
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers	7
New era in bioequivalence global harmonization through ICH M13 initiative: critical review on new concepts, alternative approaches for high-risk products	7
Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle	7
Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-M	7

Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions	7
Effects of the total flavonoid extracts and the monomers of Daphne genkwa on CYP2C8 activity	7
The effect of ARVs on the MEKKK1 gene promoter, inflammatory cytokine expression and signalling in acute treated Jurkat T cells	7
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P ₁ modulator ponesimod	7
Absorption, distribution, metabolism, and excretion of [¹⁴C]TPN729 after oral administration to rats	7
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation	7
Arctigenin-induced erythrocyte membrane remodelling is mediated through calcium influx, metabolic collapse, and casein kinase 1α	7
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain	7
In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin	6
Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats	6
Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics	6
Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications	6
Beyond cytotoxic potency: disposition features required to design ADC payload	6
2-Naphthalenemethanol participates in metabolic activation of 2-methylnaphthalene	6
2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A2	6
Development of eugenol-fortified fisetin-loaded nano-invasomes gel	6
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population	6
The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma	6
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human	6
Prediction of the neurotoxic mechanisms of the pesticide phorate using network toxicology, molecular docking, and molecular dynamics simulation	6
Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants	6
Defining the enzymes of xenobiotic metabolism – a forlorn hope?	6
Mechanism of Black American Ginseng saponins in ameliorating memory dysfunction in aging mice by activating the BDNF/PI3K/AKT/CREB pathway	6
Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study	6
Experimental and computational models to investigate intestinal drug permeability and metabolism	6
Characterisation of seven medications approved for attention-deficit/hyperactivity disorder usingin vitromodels of hepatic metabolism	5
Meeting report of the 3rd European Biotransformation Workshop	5
Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?	5
Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats	5
Preface for special issue: “Emerging strategies, technologies, and approaches for the next generation ADCs”	5
Effectiveness of pain care intervention combined with traditional Chinese medicine care in the perioperative care of patients with urinary stones	5
Human and nonclinical disposition of [¹⁴C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection	5
Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats	5
Pharmacokinetics of intranasal drugs, still a missed opportunity?	5
Interactions of organophosphorus pesticides with ATP-binding cassette (ABC) drug transporters	5
Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation	5
Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys	5
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir	5
Sanguinarine-induced proteomic changes in methicillin-resistant Staphylococcus aureus	5
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective	5
Metabolism of gartanin in liver microsomes and its modulating effects on cytochrome P450s	5
Bioavailability and dose proportionality of a highly lipophilic phenolic antioxidant	5
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species	5
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities	5
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities	4
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury	4
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	4
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration	4
Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs	4

Green Synthesis of Zinc Oxide Nanoflowers Using Camellia sinensis Extract and Evaluation of Their Xenobiotic-Like Cellular, Apoptotic, and Inflammatory R	4
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2024	4
The impact of CYP3A5 , NR1I2 , and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical	4
Perspectives on the use of machine learning for ADME prediction at AstraZeneca	4
Use of a machine learning approach to estimate pathobiological effects of crack cocaine administration in rats	4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data	4
Metabolic profiling in liver microsomes and mice of E28, a potent FLT3 inhibitor	4
Study of the urinary metabolites of 17ɑ-methyl-19-nortestosterone in human using gas chromatography – mass spectrometry. Preliminary results	4
The chlorophenoxy herbicide MCPA: a mechanistic basis for the observed differences in toxicological profile in humans and rats versus dogs	4
Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes	4
EP300/HIF-1 pathway: the key to sacubitril valsartan sodium alleviating myocardial hypoxia injury	4
Sodium dodecylbenzene sulphonate (SDBS) present in detergents: action on the gills, skin, and blood of D. rerio fish	4
Drug-drug interaction between danshensu and irbesartan and its potential mechanism	4
Response to the comments raised by Fernando Tricta	4
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)	4
Inorganic mercury pharmacokinetics in man: a hybrid model	4
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats	4
Physiologically based pharmacokinetic (PBPK) modelling and simulation based integrative approach to assess natural product-drug interactions – effect of glycyrrhetinic acid on quetiapine	4
Calycosin improves insulin resistance by regulating the hsa-miR-324-3p/AKT pathway to inhibit FOXO3a nuclear transfer	4
Metabolites identification and species comparison of Oroxylin A, an anti-cancer flavonoid, in vitro and in vivo by HPLC-Q-TOF-MS/MS	4
A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate	4
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects	4
Studies addressing potential bioactivation and genotoxicity liabilities of the N -nitroso derivative of the antidepressant paroxetine	4
Potential influence of interleukin-6 -174G/C gene polymorphism on kidney graft function and tacrolimus dose requirements: five-year follow-up	4